Interestingly, PTPRN2 CSF levels were significantly decreased in individuals with probable AD compared to individuals with SCD and MCI as well in MCI compared to SCD in the discovery cohort when comparing the sample groups based on diagnosis within the amyloid and tau defined sample groups, suggesting association to cognitive impairment independently on AT status. This evidence concerns the gene PTPRN2 and Cognitive impairment.